Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
First Claim
1. A method for identifying a therapeutic having analogous activity to a thiazolidinedione comprising contacting a cell containing a PPARγ
- receptor with a candidate therapeutic; and
determining the level of expression of at least one gene selected from the panel of genes in Table I and/or Table II, wherein an increase in the level of expression of at least one gene of Tables I or III and/or a decrease in the level of expression of at least one gene of Tables II or IV in the cell treated with the candidate therapeutic relative to a cell that was not treated with the candidate therapeutic indicates that the candidate therapeutic is a therapeutic for treating a disease associated with a PPARγ
receptor.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a method for identifying a therapeutic having analogous activity to a thiazolidinedione by contacting a cell containing a PPARγ receptor with a candidate therapeutic; and determining the level of a selected gene expression; to indicate that the candidate therapeutic is a therapeutic for treating a disease associated with a PPARγ receptor. The invention also relates to a composition comprising a plurality of selected genes or gene fragments, or a plurality of proteins or proteins fragments selected from proteins encoded by the selected genes thereof. The invention further relates to a method for determining whether a subject is responsive to treatment with a therapeutic having analogous activity to a thiazolidinedione.
-
Citations
21 Claims
-
1. A method for identifying a therapeutic having analogous activity to a thiazolidinedione comprising contacting a cell containing a PPARγ
- receptor with a candidate therapeutic; and
determining the level of expression of at least one gene selected from the panel of genes in Table I and/or Table II, wherein an increase in the level of expression of at least one gene of Tables I or III and/or a decrease in the level of expression of at least one gene of Tables II or IV in the cell treated with the candidate therapeutic relative to a cell that was not treated with the candidate therapeutic indicates that the candidate therapeutic is a therapeutic for treating a disease associated with a PPARγ
receptor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- receptor with a candidate therapeutic; and
- 11. A composition comprising a plurality of genes or gene fragments selected from the panel of genes in Tables I-IV.
- 15. A composition comprising a plurality of proteins or proteins fragments selected from proteins encoded by the panel of genes in Tables I-IV.
-
19. A method for determining whether a subject is responsive to treatment with a therapeutic having analogous activity to a thiazolidinedione, comprising determining the level of expression of a plurality of genes of Tables I or III or Tables II or IV in cells of the subject, wherein a higher level of expression of the genes of Tables I or III or a lower level of expression of the genes of Tables II or IV in the adipocytes of the subject relative to that in adipocytes of a subject that was not treated with a PPARγ
- ligand indicates that the subject is responsive to treatment with the PPARγ
ligand. - View Dependent Claims (20)
- ligand indicates that the subject is responsive to treatment with the PPARγ
-
21. A method for predicting whether a subject would be responsive to treatment with a compound having analogous activity to a thiazolidinedione, comprising incubating cells of the subject with a PPARγ
- ligand and determining the level of expression of a plurality of genes of Tables I and/or III and/or Tables II and/or IV in the cells, wherein a higher level of expression of genes of Tables I or III or lower level of expression of genes of Tables II or IV relative to expression in cells of subjects not treated with a PPARγ
ligand indicates that the subject would be responsive to treatment with the PPARγ
ligand.
- ligand and determining the level of expression of a plurality of genes of Tables I and/or III and/or Tables II and/or IV in the cells, wherein a higher level of expression of genes of Tables I or III or lower level of expression of genes of Tables II or IV relative to expression in cells of subjects not treated with a PPARγ
Specification